Alexion Pharmaceuticals (ALXN) 155.86 $ALXN
Nasdaq Up 1.7%; Bed, Bath & Beyond Sinks After Hours
at Investor's Business Daily - 2 hrs 16 mins ago
The major averages climbed more than 1% Wednesday, as more earnings reports came out after the closing bell. The Nasdaq led the way, climbing 1.7%. The Dow Jones industrial average and S&P 500 each rose 1.1%. But NYSE and Nasdaq volume was...
SmarTrend Watching for Potential Pullback in Shares of Alexion Pharmaceuticals After 5.55% Gain
Comtex SmarTrend(R) - 2 hrs 41 mins ago
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $147.35 to a high of $156.31. Yesterday, the shares gained 5.6%, which took the trading range above the 3-day high of $153.90 on volume of 1.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Stocks Extend Gains; Trimble Navigation Finds Support
at Investor's Business Daily - Wed Apr 09, 3:15PM CDT
Stocks strengthened and were near session highs Wednesday, after the minutes from the March 19 Fed meeting were released at 2 p.m. ET and revealed some dovishness among central bankers. With a little over one hour remaining in the session, the Nasdaq...
Alexion, Biogen Among Leading Big-Cap Biotechs
at Investor's Business Daily - Wed Apr 09, 7:02AM CDT
Growth stocks are taking a hit now that the market is in a correction. Biotechs saw a recent sell-off over concerns that the sector was overheating, but biotechs and medical stocks are among leading big-cap stocks. IBD's Big Cap Screen of the Day...
EPO Upholds Alnylam's McSwiggen Patent - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 6:00PM CDT
The EPO has upheld Alnylam's McSwiggen patent in oral opposition proceedings in Germany.
Encouraging Pre-Clinical Data from Celldex - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 4:40PM CDT
Celldex announced encouraging results from preclinical studies on its antibody drug conjugate, CDX-014.
Intercept Pharma Prices 1M Share Offering, Shares Down - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 4:00PM CDT
Intercept Pharmaceuticals shares fell 9.61% after the company priced a public offering of 1 million shares of its common stock at $320.00 per share.
Pipeline Update from Idenix - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 3:55PM CDT
Idenix's nucleotide polymerase inhibitor candidate, IDX21437, showed potent antiviral activity in patients suffering from hepatitis C virus (HCV) infection.
Halozyme Falls on Phase II Study Halt - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 11:10AM CDT
Halozyme's shares fell after the company announced its decision to temporarily halt patient enrollment and dosing of PEGPH20 in phase II study.
Bristol-Myers Seeks FDA Approval for HCV Candidates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 10:40AM CDT
Bristol-Myers has filed NDAs with the FDA for HCV candidates, daclatasvir and asunaprevir.
FDA Target Date for Gilead's HCV Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 10:30AM CDT
Gilead is looking to bring a fixed-dose combination of Sovaldi and ledipasvir into the market for treating HCV.
RadNet Touches New 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 9:26AM CDT
RadNet's adjusted earnings per share beat the Zacks Consensus Estimate by 8 cents.
The Zacks Analyst Blog Highlights: Facebook, Tesla Motors, Amazon.com, Netflix and Alexion Pharmaceuticals
PR Newswire - Tue Apr 08, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Facebook, Inc. (Nasdaq:FB-Free Report), Tesla Motors, Inc. (Nasdaq:TSLA-Free Report), Amazon.com Inc. (Nasdaq:AMZN-Free Report), Netflix, Inc. (Nasdaq:NFLX-Free Report) and Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN-Free Report).
MannKind Slips on Afrezza Approval Delay - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 7:52AM CDT
The PDUFA date for MannKind's Afrezza was pushed back by the FDA by three months to Jul 15.
Idenix Pharmaceuticals (IDIX) Jumps: Stock Up 12.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 7:51AM CDT
Idenix Pharmaceuticals Inc. was a big mover last session, as its shares rose over 12% on the day.
Puma Biotechnology (PBYI) in Focus: Stock Tumbles 18.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 7:45AM CDT
Puma Biotechnology has seen negative consensus estimates for the current quarter along with a significant decline in its share price for the past month
Questcor Pharmaceuticals (QCOR) Shows Strength: Stock Surges 18.7% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 7:44AM CDT
Questcor Pharmaceuticals, Inc. was a big mover last session, as the company saw its shares shoot up nearly 19% on the day.
Tweet of the Week: Big Biotech Dominates Industry Gains
Brian Orelli and Max Macaluso, The Motley Fool - Motley Fool - Mon Apr 07, 4:25PM CDT
This week's tweet comes from Bruce Booth (@LifeSciVC), who points out analysts at Bernstein concluded that just six companies contributed to 77% of the increase in value of the biotech sector over the past three years. There's no doubt that Amgen...
Momentum Slide to Continue for Netflix, Facebook? - Analyst Blog
Swarup Gupta - Zacks Investment Research - Mon Apr 07, 12:21PM CDT
Momentum stocks may soon bounce back, but for now earnings hold the key.
/C O R R E C T I O N -- BioMed Realty/
PR Newswire - Mon Apr 07, 12:06PM CDT
In the news release, BioMed Realty Invests In Life Science Research Facilities Leased To Yale University, Yale-New Haven Hospital And Alexion Pharmaceuticals, issued 07-Apr-2014 by BioMed Realty over PR Newswire, we are advised by the company that the 4th paragraph, 1st sentence, should read "...a global pharmaceutical company with a marketed product, Soliris®..." rather than, "...a global pharmaceutical company with a marketed product, Solaris®..." as originally issued inadvertently. The complete, corrected release follows:
Nasdaq Up 1.7%; Bed, Bath & Beyond Sinks After Hours
at Investor's Business Daily - 2 hrs 16 mins ago
The major averages climbed more than 1% Wednesday, as more earnings reports came out after the closing bell. The Nasdaq led the way, climbing 1.7%. The Dow Jones industrial average and S&P 500 each rose 1.1%. But NYSE and Nasdaq volume was...
SmarTrend Watching for Potential Pullback in Shares of Alexion Pharmaceuticals After 5.55% Gain
Comtex SmarTrend(R) - 2 hrs 41 mins ago
Alexion Pharmaceuticals (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $147.35 to a high of $156.31. Yesterday, the shares gained 5.6%, which took the trading range above the 3-day high of $153.90 on volume of 1.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Stocks Extend Gains; Trimble Navigation Finds Support
at Investor's Business Daily - Wed Apr 09, 3:15PM CDT
Stocks strengthened and were near session highs Wednesday, after the minutes from the March 19 Fed meeting were released at 2 p.m. ET and revealed some dovishness among central bankers. With a little over one hour remaining in the session, the Nasdaq...
Alexion, Biogen Among Leading Big-Cap Biotechs
at Investor's Business Daily - Wed Apr 09, 7:02AM CDT
Growth stocks are taking a hit now that the market is in a correction. Biotechs saw a recent sell-off over concerns that the sector was overheating, but biotechs and medical stocks are among leading big-cap stocks. IBD's Big Cap Screen of the Day...
EPO Upholds Alnylam's McSwiggen Patent - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 6:00PM CDT
The EPO has upheld Alnylam's McSwiggen patent in oral opposition proceedings in Germany.
Encouraging Pre-Clinical Data from Celldex - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 4:40PM CDT
Celldex announced encouraging results from preclinical studies on its antibody drug conjugate, CDX-014.
Intercept Pharma Prices 1M Share Offering, Shares Down - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 4:00PM CDT
Intercept Pharmaceuticals shares fell 9.61% after the company priced a public offering of 1 million shares of its common stock at $320.00 per share.
Pipeline Update from Idenix - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 3:55PM CDT
Idenix's nucleotide polymerase inhibitor candidate, IDX21437, showed potent antiviral activity in patients suffering from hepatitis C virus (HCV) infection.
Halozyme Falls on Phase II Study Halt - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 11:10AM CDT
Halozyme's shares fell after the company announced its decision to temporarily halt patient enrollment and dosing of PEGPH20 in phase II study.
Bristol-Myers Seeks FDA Approval for HCV Candidates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 10:40AM CDT
Bristol-Myers has filed NDAs with the FDA for HCV candidates, daclatasvir and asunaprevir.
FDA Target Date for Gilead's HCV Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 10:30AM CDT
Gilead is looking to bring a fixed-dose combination of Sovaldi and ledipasvir into the market for treating HCV.
RadNet Touches New 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 9:26AM CDT
RadNet's adjusted earnings per share beat the Zacks Consensus Estimate by 8 cents.
The Zacks Analyst Blog Highlights: Facebook, Tesla Motors, Amazon.com, Netflix and Alexion Pharmaceuticals
PR Newswire - Tue Apr 08, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Facebook, Inc. (Nasdaq:FB-Free Report), Tesla Motors, Inc. (Nasdaq:TSLA-Free Report), Amazon.com Inc. (Nasdaq:AMZN-Free Report), Netflix, Inc. (Nasdaq:NFLX-Free Report) and Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN-Free Report).
MannKind Slips on Afrezza Approval Delay - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 7:52AM CDT
The PDUFA date for MannKind's Afrezza was pushed back by the FDA by three months to Jul 15.
Idenix Pharmaceuticals (IDIX) Jumps: Stock Up 12.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 7:51AM CDT
Idenix Pharmaceuticals Inc. was a big mover last session, as its shares rose over 12% on the day.
Puma Biotechnology (PBYI) in Focus: Stock Tumbles 18.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 7:45AM CDT
Puma Biotechnology has seen negative consensus estimates for the current quarter along with a significant decline in its share price for the past month
Questcor Pharmaceuticals (QCOR) Shows Strength: Stock Surges 18.7% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 7:44AM CDT
Questcor Pharmaceuticals, Inc. was a big mover last session, as the company saw its shares shoot up nearly 19% on the day.
Tweet of the Week: Big Biotech Dominates Industry Gains
Brian Orelli and Max Macaluso, The Motley Fool - Motley Fool - Mon Apr 07, 4:25PM CDT
This week's tweet comes from Bruce Booth (@LifeSciVC), who points out analysts at Bernstein concluded that just six companies contributed to 77% of the increase in value of the biotech sector over the past three years. There's no doubt that Amgen...
Momentum Slide to Continue for Netflix, Facebook? - Analyst Blog
Swarup Gupta - Zacks Investment Research - Mon Apr 07, 12:21PM CDT
Momentum stocks may soon bounce back, but for now earnings hold the key.
/C O R R E C T I O N -- BioMed Realty/
PR Newswire - Mon Apr 07, 12:06PM CDT
In the news release, BioMed Realty Invests In Life Science Research Facilities Leased To Yale University, Yale-New Haven Hospital And Alexion Pharmaceuticals, issued 07-Apr-2014 by BioMed Realty over PR Newswire, we are advised by the company that the 4th paragraph, 1st sentence, should read "...a global pharmaceutical company with a marketed product, Soliris®..." rather than, "...a global pharmaceutical company with a marketed product, Solaris®..." as originally issued inadvertently. The complete, corrected release follows:
